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Abstract
The overall goal of this study was to provide evidence for the clinical validity of nine genetic 
variants in five genes previously associated with irinotecan neutropenia and pharmacokinetics. 
Variants associated with absolute neutrophil count (ANC) nadir and/ or irinotecan 
pharmacokinetics in a discovery cohort of cancer patients were genotyped in an independent 
replication cohort of 108 cancer patients. Patients received single-agent irinotecan every 3 weeks. 
For ANC nadir, we replicated UGT1A1*28, UGT1A1*93 and SLCO1B1*1b in univariate analyses. 
For irinotecan area under the concentration–time curve (AUC0-24), we replicated ABCC2 -24C>T; 
however, ABCC2 -24C>T only predicted a small fraction of the variance. For SN-38 AUC0-24 and 
the glucuronidation ratio, we replicated UGT1A1*28 and UGT1A1*93. In addition to 
UGT1A1*28, this study independently validated UGT1A1*93 and SLCO1B1*1b as new predictors 
of irinotecan neutropenia. Further demonstration of their clinical utility will optimize irinotecan 
therapy in cancer patients.
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INTRODUCTION
Irinotecan is an anticancer agent commonly used for the treatment of metastatic colorectal 
cancer and other solid tumors. Irinotecan is a potent inhibitor of topoisomerase I, and is 
initially hydrolyzed to its active metabolite, SN-38, which is then subsequently inactivated 
through UGT1A1-mediated glucuronidation. A significant proportion of patients treated 
with irinotecan develop toxicities, including severe neutropenia. Neutropenia is a common, 
serious, dose-dependent and dose-limiting toxicity of irinotecan.1
A common, germline genetic variation in UGT1A1 predisposes patients to an increased risk 
of irinotecan-induced toxicities.2,3 The number of TA repeats in the UGT1A1 promoter is 
inversely proportional to the transcriptional efficiency of the gene,4 mRNA expression5 and 
protein levels.6 Patients with the UGT1A1*28 variant have seven TA repeats (compared 
with six repeats in patients with UGT1A1*1), have decreased SN-38 glucuronidation7 and 
experience increased systemic exposure to SN-38, which results in a higher risk of severe 
neutropenia.1 As a result, an FDA-approved UGT1A1*28 genotyping test has been made 
commercially available,8 and the irinotecan label has been revised to include UGT1A1*28 as 
a predisposing factor for severe neutropenia.9
Irinotecan-induced neutropenia is a complex, polygenic phenotype. There is significant 
interindividual variation in systemic exposure to both irinotecan and SN-38 that cannot be 
explained solely by UGT1A1*28. Several additional genetic variants contribute to both 
variability in irinotecan pharmacokinetics and the risk of severe neutropenia.10-16 The FDA-
approved UGT1A1*28 genetic test has only moderate predictive power for severe toxicity 
due to its low positive predictive value,8 and therefore the genetic test has not been 
incorporated into routine clinical practice. The discovery of additional variants associated 
with neutropenia is needed to improve the utilization of irinotecan genetic testing.
Pharmacogenetic studies have identified a vast set of genetic variants as predictors of 
chemotherapy efficacy and toxicity. The majority of these proposed variants have failed to 
produce similar results across different studies, which has limited the clinical utility of 
pharmacogenetics.17,18 Therefore, prospective replication of pharmacogenetic findings in 
independent and external cohorts of patients is essential to hasten the implementation of 
pharmacogenetics into routine clinical practice.
In a previous study of cancer patients treated with single-agent irinotecan, novel gene 
variants that were associated with irinotecan disposition and toxicity were identified.16 In 
addition to UGT1A1*28, other variants, mostly in drug transporter genes, were associated 
with neutropenia and irinotecan pharmacokinetics. Therefore, we conducted a replication 
study to test the clinical validity of these variants in an external cohort of cancer patients 
treated with single-agent irinotecan.
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MATERIALS AND METHODS
Study design
The overall goal of the study was to replicate genetic associations for irinotecan neutropenia 
and pharmacokinetics previously identified in a discovery cohort.16 The primary objective 
was to validate the associations between four genetic variants and absolute neutrophil count 
(ANC) nadir by testing them in an external replication cohort. The secondary objective was 
to validate the effects of eight genetic variants previously associated with pharmacokinetic 
parameters in the discovery cohort by analyzing them in the replication cohort. Thus, a total 
of nine common variants in five genes (ANC nadir and the pharmacokinetic phenotypes 
shared two variants) were genotyped in the replication cohort and tested for associations. 
Variants for replication testing were selected based on significant genotype–phenotype 
associations (P ≤ 0.05) observed in the discovery cohort. All patients in the replication 
cohort were White, and therefore only the previously genotyped White patients comprised 
the discovery cohort (n = 67).16
Patient characteristics
In the discovery cohort, advanced solid tumor patients were treated at the University of 
Chicago (Chicago, IL, USA) with a 90-min infusion of single-agent irinotecan every 3 
weeks at 300 mg m−2 (n = 18) or 350 mg m−2 (n = 49). Eligibility criteria included adequate 
hematopoietic function (white blood cell count ≥ 3500 per μl, ANC ≥ 1500 per μl, platelets 
≥100 000 per μl), normal renal and hepatic function (creatinine ≤ 1.5 mg dl−1, total bilirubin 
≤ 1.25 × upper limit of normal (ULN), and AST/ALT < 5 × ULN), and adequate 
performance status (Karnofsky score ≥ 70%). Plasma pharmacokinetic parameters of 
irinotecan and metabolites were measured during and after the first cycle infusion of 
irinotecan. Forty-two genetic variants in twelve candidate genes of the irinotecan pathway 
were previously genotyped and tested for association with irinotecan pharmacokinetics and 
ANC nadir, measured during cycle 1.
In the replication cohort, 108 White advanced solid tumor patients were treated at the 
Erasmus University Medical Center, Erasmus MC Cancer Institute (Rotterdam, The 
Netherlands).19-21 Patients received a 90-min infusion of single-agent irinotecan every 3 
weeks at 600 mg (flat dose, n = 58), 350 mg m−2 (n = 31), or 380–1060 mg (flat dose 
calculated according to an algorithm,19 n = 19). Eligibility criteria included adequate 
hematopoietic function (ANC ≥ 2000 per μl, platelets ≥ 100 000 per μl) and normal renal 
and hepatic function (creatinine clearance ≥ 60 ml min−1, total bilirubin ≤ 1.25 × ULN and 
AST/ALT ≤ 3 × ULN). Plasma pharmacokinetics of irinotecan and metabolites were 
measured during and after the first cycle infusion.
All patients in the discovery and replication cohorts provided written informed consent and 
the local institutional review boards approved the clinical protocols. Patient characteristics 
from the discovery and replication cohorts are provided in Table 1.
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Patient phenotyping: pharmacokinetic parameters and ANC nadir
In both cohorts, pharmacokinetic parameters included: irinotecan area under the 
concentration–time curve to the last time of sampling (AUC0-24), AUC0-24 of the active 
SN-38 metabolite, AUC0-24 of the inactive SN-38 glucuronide (SN-38G) and the ratio of 
SN-38G AUC0-24 to SN-38 AUC0-24 (glucuronidation ratio).
For the discovery cohort, samples were collected on day 1 of cycle 1 at baseline before 
irinotecan infusion, during the infusion (30, 60 and 90 min), and after the infusion (10, 20, 
30 and 45 min, 1, 1.5, 2, 4, 6, 8, 12 and 24 h). Plasma concentrations of irinotecan and 
metabolites were measured, as previously reported.10 Pharmacokinetic parameters were 
calculated by non-compartmental analysis (WinNonlin, Pharsight, Cary, NC, USA).
For the replication cohort, samples were collected on day 1 of cycle 1 at baseline before 
infusion, during the infusion (30 and 90 min) and after the infusion (10, 20 and 30 min, and 
1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 and 24 h). Plasma concentrations of irinotecan and metabolites 
were measured, as previously reported.20,22,23 Pharmacokinetic parameters were calculated 
by non-compartmental analysis (PK Solutions v2.0, Summit Research Services, Montrose, 
CO, USA).
In both cohorts, complete blood counts were taken at baseline, weekly throughout cycle 1, 
and then before the start of cycle 2 to obtain the measurements of the ANC nadir.
Genotype data
Nine common variants, previously associated with irinotecan pharmacokinetics and ANC 
nadir in the discovery cohort, were genotyped in the replication cohort: ABCB1 IVS9 44 
A>G, ABCC1 1684 T>C, ABCC1 IVS11 -48C>T, ABCC2 3972C>T, ABCC2 -24C>T, 
SLCO1B1*1b, SLCO1B1*5, UGT1A1*28 and UGT1A1*93. DNA isolated from peripheral 
blood was used for genotyping. All genotyping assays were performed on an Applied 
Biosystems TaqMan 7500 (Life Technologies, Grand Island, NY, USA). UGT1A1*93 was 
genotyped by restriction fragment length polymorphism PCR, using 5′-
ACCTCTAGTTACATAACCTGAA-3′ as the forward primer sequence and 5′-
ATAAACCCGACCTCACCAC-3′ as the reverse primer sequence. UGT1A1*28 genotyping 
methods for the replication cohort have been previously described.20 All other variants were 
genotyped using TaqMan SNP genotyping assays (Life Technologies) as per the 
manufacturer’s instructions. Positive controls of known genotypes were used in the assays.
Statistics
Data for all phenotypes for both cohorts were log10 transformed. Hardy–Weinberg 
Equilibrium was evaluated for all nine variants genotyped in both the discovery and 
replication cohorts (Supplementary Table 1). In the discovery cohort, associations between 
genetic variants and clinical phenotypes were analyzed using linear regression, and were 
adjusted for sex, age and irinotecan dose (300 or 350 mg m −2). All ANC nadir analyses 
were also adjusted for baseline ANC.
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In the replication cohort, we prospectively tested associations between the nine gene variants 
described above and phenotypes of ANC nadir and irinotecan pharmacokinetics. The same 
statistical methodologies employed for the discovery cohort were applied: linear regression 
adjusted for sex, age and irinotecan dose (350 mg m−2, 600 mg flat dose or dose by an 
algorithm19), with baseline ANC used to adjust the ANC nadir analysis. Flat doses were 
converted to mg m−2 according to the body-surface area of each patient. The same mode of 
inheritance (dominant, recessive or additive) used in the discovery cohort was also used in 
the replication cohort.
No general consensus exists to provide standardized criteria for replication cohort analyses. 
We considered a given variant’s association to be replicated based on direct comparison of 
the observed estimates of effect in the discovery and replication cohorts: an association’s 
estimate of effect in the replication cohort had to be in the same direction as in the discovery 
cohort (an increased or decreased estimate of phenotype change in both cohorts), and lie 
within the 95% confidence interval (CI) of the discovery cohort’s estimate. Two-sided P-
values are reported for reference. Since comparisons between discovery and replication 
cohort estimates of effect were pre-specified and rely on 95% CIs from the discovery cohort, 
not on hypothesis testing in the replication cohort, issues related to multiplicity are not 
present. Therefore, no correction for multiple comparisons was performed.
RESULTS
This study sought to replicate, in an independent, external cohort of White cancer patients 
from the Netherlands, nine variants from five genes that had previously associated with 
ANC nadir or irinotecan pharmacokinetics.16 Baseline clinical patient characteristics and 
pharmacokinetic data (Table 1), as well as allele and genotype frequencies (Supplementary 
Table 1), were comparable between the two cohorts. Below we report the replication results 
of each variant for neutropenia and irinotecan pharmacokinetics (Table 2).
Replication of variants previously associated with ANC nadir
For ANC nadir, four variants that previously associated with ANC nadir in the discovery 
cohort were tested in the replication cohort. In the discovery cohort, UGT1A1*28 (additive 
model), UGT1A1*93 (recessive model) and ABCC1 IVS11 -48C>4 T (recessive model) 
were associated with decreased ANC nadir; SLCO1B1*1b (dominant model) was associated 
with increased ANC nadir. In the replication cohort, we considered UGT1A1*28, 
UGT1A1*93 and SLCO1B1*1b replicated, since the direction of the estimate of the effect 
for each variant was consistent between both cohorts (decreased ANC nadir for UGT1A1*28 
and UGT1A1*93, as well as increased ANC nadir for SLCO1B1*1b) and each was within 
the 95% CIs for its respective discovery cohort estimate. ABCC1 IVS11 -48C>T failed to 
replicate (Table 2).
Replication of variants associated with the pharmacokinetic parameters of irinotecan
For irinotecan AUC0-24, two variants that were previously associated with irinotecan 
AUC0-24 in the discovery cohort were tested in the replication cohort. In the discovery 
cohort, ABCC2 -24C>T and SLCO1B1*5 (both dominant model) were associated with 
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increased irinotecan AUC0-24. In the replication cohort, we considered ABCC2 -24C>T 
replicated since the direction of the estimate of the effect was consistent between both 
cohorts (increased AUC0-24 for both variants), and was within the 95% CIs for the discovery 
cohort estimate. SLCO1B1*5 failed to replicate (Table 2).
For SN-38 AUC0-24, three variants that were previously associated with SN-38 AUC0-24 in 
the discovery cohort were tested in the replication cohort. In the discovery cohort, 
UGT1A1*28 and UGT1A1*93 (both additive model) were associated with increased SN-38 
AUC0-24, while ABCB1 IVS9> -44A>G (dominant model) was associated with decreased 
SN-38 AUC0-24. In the replication cohort, we considered UGT1A1*28 and UGT1A1*93 
replicated since the direction of the estimate of the effect for each variant was consistent 
between both cohorts (increased AUC0-24 for both variants), and each was within the 95% 
CIs for its respective discovery cohort estimate. ABCB1 IVS9 -44A> G failed to replicate 
(Table 2).
For SN-38G AUC0-24, although ABCC2 3972C>T (recessive model) was associated with 
increased SN-38G AUC0-24 in the discovery cohort, it failed to replicate when tested in the 
replication cohort (Table 2).
For the glucuronidation ratio, three variants that associated with the glucuronidation ratio in 
the discovery cohort were tested in the replication cohort. In the discovery cohort, 
UGT1A1*28 (additive model), UGT1A1*93 (additive model) and ABCC1 1684T>C 
(dominant model) were associated with a decreased glucuronidation ratio. In the replication 
cohort, we considered UGT1A1*28 and UGT1A1*93, replicated, since the direction of the 
estimate of the effect for each variant was consistent between both cohorts (decreased 
glucuronidation ratio for all variants), and each was within the 95% CIs for its respective 
discovery cohort estimate. Although the association between ABCC1 1684 T>C (dominant 
model) and glucuronidation ratio also satisfies our criteria for replication, we are less 
convinced of the association, given the 84% reduction in the magnitude of the estimate as 
compared with that of the discovery cohort (Table 2).
DISCUSSION
In this replication study, we validated the clinical effects of new germline genetic variants 
for neutropenia and irinotecan pharmacokinetics using an independent, external cohort of 
White cancer patients treated with single-agent irinotecan.
The most important result of this study was the clinical validation of SLCO1B1*1b. To our 
knowledge, this provides the first replicated data implicating SLCO1B1*1b as a protective 
marker against irinotecan-induced neutropenia. SLCO1B1 encodes for organic anion 
transporter family member 1B1 (OATP1B1), and mediates hepatic uptake of both 
endogenous24,25 and xenobiotic compounds.26 OATP1B1 is a hepatic uptake transporter of 
SN-38,27,28 but not irinotecan.28 In this study, we have replicated results from the discovery 
cohort, and have shown that the variant *1b allele was associated with a higher ANC nadir 
compared with the reference sequence *1a allele (Figure 1a). Since SLCO1B1*1b is a non-
synonymous variant (asparagine to aspartate amino-acid change), and SLCO1B1 is primarily 
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expressed in the liver,29 we postulate this variant might associate with reduced neutropenia 
by altering systemic SN-38 exposure. The effect of SLCO1B1*1b on SN-38 AUC0-24 was − 
0.083 ± 0.076 (mean ± s.e.) in the White patients of the discovery cohort (n = 67; P = 
0.278), and because the P-value was >0.05, this association was not selected for analysis in 
the replication cohort. However, an exploratory univariate analysis (adjusted for dose (mg 
m −2), age and sex) revealed that SLCO1B1*1b was associated with decreased SN-38 
AUC0-24 in the replication cohort (n = 84; − 0.128 ± 0.055, P = 0.023). These results 
support the hypothesis that the protective effect of SLCO1B1*1b against neutropenia could 
be due to increased hepatic uptake of SN-38, resulting in increased SN-38 elimination from 
the plasma after irinotecan infusion.
While the pharmacokinetic data are supportive of the protective effect of SLCO1B1*1b 
against neutropenia, the functional effect of this variant is less clear. Using RNA expression 
data from human livers,30 SLCO1B1*1b (as well as variants in linkage disequilibrium r2 ≥ 
0.8) did not associate with changes in the mRNA expression of SLCO1B1 (results not 
shown). In oocyte studies, the uptake of SN-38 was higher for SLCO1B1*1b than 
SLCO1B1*1a (the reference sequence allele), but the observed difference was not 
statistically significant (see Figure 6a of Nozawa et al.28). Our results provide evidence that 
SLCO1B1*1b results in a gain of function, which leads to increased hepatic uptake of SN-38 
from the plasma. Although this seems the most plausible hypothesis, other mechanisms 
related to the widespread functions of this transporter on several endogenous constituents 
cannot be ruled out.
Another important conclusion of this study is that UGT1A1*93 confers an increased risk of 
irinotecan-induced neutropenia. We replicated results from the discovery cohort, and have 
shown that the *93 variant was associated with a lower ANC nadir compared with the 
reference sequence *1 allele (Figure 1b). UGT1A1*93 is a − 3156G>A change discovered 
during a resequencing study of the region 5′ to the UGT1A exon 1.31 According to an 
analysis of more than 150 human livers where genome-wide genotyping data were available, 
UGT1A1*93 is a major determinant of decreased levels of the UGT1A1 protein (Pearson’s r 
= − 0.46, P = 3.5 × 10−9),30,32 and additional preliminary data corroborate these findings.33 
Because UGT1A1*93 is in partial linkage disequilibrium with UGT1A1*28 among White 
patients (r2 = 0.68),34 our results suggest that UGT1A1*93, based on its greater estimate of 
effect for ANC nadir, may be a more robust marker for neutropenia than UGT1A1*28 (Table 
2). While the UGT1A1*93 variant has not yet been included in the FDA-revised irinotecan 
label, we envision that recommendations supporting UGT1A1*93 genotyping could 
eventually replace UGT1A1*28 in the irinotecan drug label.
The association between ABCC2 -24C>T and increased irinotecan AUC0-24 was also 
replicated (Figure 1c). ABCC2 encodes for the multidrug resistant protein-2 and contributes 
to the biliary clearance of irinotecan, SN-38 and SN-38G.35,36 The -24C>T variant has been 
associated with a nearly 20% reduction in promoter activity.37 This observation is consistent 
with our results, where the variant T allele was associated with increased irinotecan 
AUC0-24, likely due to decreased biliary clearance. However, the estimate of effect size was 
relatively small (Table 2), and additional studies should be conducted to elucidate the extent 
of its clinical relevance.
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Established criteria for conducting pharmacogenetic replication studies do not currently 
exist, but we provide a general framework for conducting such studies. Pharmacogenetic 
replication studies are beset with numerous challenges, including dosing and population 
heterogeneity between the discovery and replication cohorts. In our study, we attempted to 
control for population heterogeneity by comparing patients in the replication cohort to only 
the White patients from the original discovery cohort.16 Dosing heterogeneity between the 
two cohorts may have affected our ability to replicate some variants, but it did not confound 
all associations, as evidenced by the detection of associations serving as ‘positive controls’, 
such as UGT1A1*28 versus SN-38 AUC0-24 and UGT1A1*28 versus glucuronidation ratio 
(but not irinotecan AUC0-24). Moreover, we are confident that dosing heterogeneity did not 
significantly confound our replication results because irinotecan has been shown to 
demonstrate dose linear pharmacokinetics over a wide range of doses.38 Regarding our 
statistical approach, the assessment of replicated associations is not based on hypothesis 
testing, and therefore using P-values as our main criteria for replication would have been 
inappropriate. Moreover, given the influence of sample size on P-values, utilization of P-
values as the main criteria for replication could have resulted in false negative results. We 
also cannot exclude the possibility that between-cohort differences limited our ability to 
detect phenotypic differences and replicate several variants.
This replication study allowed us to demonstrate the clinical validity of associations between 
UGT1A1*93 and SLCO1B1*1b and neutropenia. The effects of these two variants on 
neutropenia should be confirmed in studies where irinotecan is given in combination with 
other anticancer agents that have neutropenic effects (for example, with 5-fluorouracil). 
Additionally, the effects of these replicated variants can currently be applied only to White 
patients. Efforts should be made to validate these variants in patients from other races who 
receive irinotecan. Further validation of their clinical utility will aid in the implementation 
of routine irinotecan pharmacogenetic testing and optimization of personalized treatments 
for cancer patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Associations between SLCO1B1*1b and absolute neutrophil count (ANC) nadir (a), 
UGT1A1*93 and ANC nadir (b) and ABCC2 -24C>T and log10 irinotecan area under the 
concentration–time curve (AUC0-24) (c) in the replication cohort. For the purpose of 
illustrating the replicated genetic associations, the data are not adjusted for the same factors 
used in the univariate analyses, and the differences among genotypes might not be the same 
as the ones reported in Table 2. ANC nadir is normalized to the baseline pretreatment ANC. 
Data are expressed as medians, 25th and 75th percentiles, minimums and maximums.
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Table 1
Baseline patient characteristics and pharmacokinetic data from the discovery and the replication cohorts
Discovery cohort (n = 67) Replication cohort (n = 108)
Dose
 300 mg m−2 18 (26.9%) —
 350 mg m−2 49 (73.1%) 31 (29.7%)
 Flat dose (600 mg) — 58 (53.7%)
 Dose by algorithm (380–1060 mg) — 19 (17.1%)
Sex
 Male 42 (62.7%) 60 (55.6%)
 Female 25 (37.3%) 48 (44.4%)
Median Range Median Range
Age (years) 57 34–85 58 26–75
BSA (m2) 1.87 146–2.55 1.88 1.36–2.50
Baseline ANC (cells per μl) 5.27 2.18–14.36 5.12 1.30–13.60
ANC Nadir (cells per μl) 2.21 0.05–7.83 1.79 0.03–7.13
Pharmacokinetic parameters Mean Range Mean Range
Irinotecan AUC0-24 (h ng ml−1) 23251 8857–65305 22776 11422–67560
SN-38 AUC0-24 (h ng ml−1) 385 38–1957 364 79–1776
SN-38G AUC0-24 (h ng ml−1) 1824 360–8214 2238 396–6912
SN-38G AUC0-24 to SN-38 AUC0-24 ratio (glucuronidation ratio) 5.85 0.78–37.57 7.32 1–24.07
Abbreviations: ANC, absolute neutrophil count; AUC, area under the concentration–time curve. Flat dosing and dosing by algorithm19 were used 
only in the replication cohort. The distribution of the algorithm-derived doses includes: 380 mg (n = 1), 500 mg (n = 1), 520 mg (n = 2), 540 mg (n 
= 1), 560 mg (n = 1), 620 mg (n =2), 640 mg (n =1), 660 mg (n =1), 680 mg (n =1), 720 mg (n = 2), 740 mg (n = 3), 780 mg (n =1), 900 mg (n =1) 
and 1060 mg (n = 1).
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